>Is MNTA working on a single isoform of heparin, or a carefully designed and reproducible set of the multiple forms found in vivo?<
The latter (a complex mixture).
>The wide range of heparin forms found in vivo might imply variability is useful. How do you decide what is best?<
Using proprietary analytics and informatics developed just for this purpose. This is why I’ve referred to MNTA as a story stock—we do not yet know how well these tools work in practice.
Market Data 
Markets 
AI
